BillionToOne Rejects Short Seller's Claims, Weighs Legal Action
BLLN sits 48% above its 52-week low of $61.96 on elevated volume (2.3× avg).
Summary
BillionToOne formally rejected Fuzzy Panda Research's November 18 short report, calling its claims inaccurate, distorted and reliant on anonymous sources and selectively presented data. The company said it is reviewing the report with legal advisors and considering all available legal options. This is the company's first substantive rebuttal after shares fell 10% on the report earlier today. The response defends billing, patient financial assistance and commercial practices as compliant, and CEO Oguzhan Atay stood behind the company's testing and disclosures. The rebuttal contains no new financial figures or operational disclosures, so it addresses reputation and legal risk rather than the underlying business.
At the time of this announcement, BLLN was trading at $91.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $61.96 to $150.44. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.